Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105


Oncogenic signaling of MEK5-ERK5.

Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME.

Cancer Lett. 2017 Apr 28;392:51-59. doi: 10.1016/j.canlet.2017.01.034. Epub 2017 Jan 30. Review.


Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.

Gestaut MM, Antoon JW, Burow ME, Beckman BS.

Pharmacol Rep. 2014 Feb;66(1):174-8. doi: 10.1016/j.pharep.2013.08.014. Epub 2014 Feb 3.


3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.

Ponnapakam AP, Liu J, Bhinge KN, Drew BA, Wang TL, Antoon JW, Nguyen TT, Dupart PS, Wang Y, Zhao M, Liu YY, Foroozesh M, Beckman BS.

Bioorg Med Chem. 2014 Feb 15;22(4):1412-20. doi: 10.1016/j.bmc.2013.12.065. Epub 2014 Jan 8.


Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.

White MD, Chan L, Antoon JW, Beckman BS.

Anticancer Res. 2013 Sep;33(9):3573-9.


MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.


A review of ceramide analogs as potential anticancer agents.

Liu J, Beckman BS, Foroozesh M.

Future Med Chem. 2013 Aug;5(12):1405-21. doi: 10.4155/fmc.13.107. Review.


Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells.

Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME.

Mol Carcinog. 2014 Jan;53(1):38-48. doi: 10.1002/mc.21946. Epub 2012 Aug 21.


Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Antoon JW, White MD, Driver JL, Burow ME, Beckman BS.

Exp Biol Med (Maywood). 2012 Jul;237(7):832-44. doi: 10.1258/ebm.2012.012028. Epub 2012 Aug 2.


Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance.

Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME.

Sci Rep. 2012;2:539. doi: 10.1038/srep00539. Epub 2012 Jul 27.


Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

Collins-Burow BM, Antoon JW, Frigo DE, Elliott S, Weldon CB, Boue SM, Beckman BS, Curiel TJ, Alam J, McLachlan JA, Burow ME.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):186-93. doi: 10.1016/j.jsbmb.2012.05.004. Epub 2012 May 24.


Gαo potentiates estrogen receptor α activity via the ERK signaling pathway.

Bratton MR, Antoon JW, Duong BN, Frigo DE, Tilghman S, Collins-Burow BM, Elliott S, Tang Y, Melnik LI, Lai L, Alam J, Beckman BS, Hill SM, Rowan BG, McLachlan JA, Burow ME.

J Endocrinol. 2012 Jul;214(1):45-54. doi: 10.1530/JOE-12-0097. Epub 2012 May 4.


Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance.

Antoon JW, White MD, Burow ME, Beckman BS.

Oncol Rep. 2012 Jun;27(6):1779-86. doi: 10.3892/or.2012.1743. Epub 2012 Mar 27.


Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer.

Antoon JW, Beckman BS.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2624-8. doi: 10.1016/j.bmcl.2012.01.087. Epub 2012 Jan 28.


Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives.

Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS.

Cancer Invest. 2012 Feb;30(2):135-48. doi: 10.3109/07357907.2011.636116. Review.


MEK5/ERK5 pathway: the first fifteen years.

Drew BA, Burow ME, Beckman BS.

Biochim Biophys Acta. 2012 Jan;1825(1):37-48. doi: 10.1016/j.bbcan.2011.10.002. Epub 2011 Oct 13. Review.


Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.

Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS.

J Mol Endocrinol. 2011 Apr 28;46(3):205-16. doi: 10.1530/JME-10-0116. Print 2011 Jun.


Sphingosine kinase: a promising cancer therapeutic target.

Antoon JW, Beckman BS.

Cancer Biol Ther. 2011 Apr 1;11(7):647-50. Epub 2011 Apr 1. No abstract available.


Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.

Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, Smith CD, Burow ME, Beckman BS.

Cancer Biol Ther. 2011 Apr 1;11(7):678-89. Epub 2011 Apr 1.


Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.

Cancer Res. 2011 Jan 15;71(2):603-13. doi: 10.1158/0008-5472.CAN-10-3185. Epub 2010 Dec 1. Erratum in: Cancer Res. 2011 May 1;71(9):3432.


Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME.

Mol Cancer. 2010 Nov 18;9:295. doi: 10.1186/1476-4598-9-295.


Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS.

Endocrinology. 2010 Nov;151(11):5124-35. doi: 10.1210/en.2010-0420. Epub 2010 Sep 22.


Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival.

Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, McLachlan JA, Burow ME.

Int J Oncol. 2010 Sep;37(3):541-50.


Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides.

Liu J, Antoon JW, Ponnapakkam A, Beckman BS, Foroozesh M.

Bioorg Med Chem. 2010 Jul 15;18(14):5316-22. doi: 10.1016/j.bmc.2010.05.044. Epub 2010 Jun 8.


Inhibition of p53 sensitizes MCF-7 cells to ceramide treatment.

Struckhoff AP, Patel B, Beckman BS.

Int J Oncol. 2010 Jul;37(1):21-30.


Glyceollin I enantiomers distinctly regulate ER-mediated gene expression.

Payton-Stewart F, Khupse RS, Boué SM, Elliott S, Zimmermann MC, Skripnikova EV, Ashe H, Tilghman SL, Beckman BS, Cleveland TE, McLachlan JA, Bhatnagar D, Wiese TE, Erhardt P, Burow ME.

Steroids. 2010 Dec;75(12):870-8. doi: 10.1016/j.steroids.2010.05.007. Epub 2010 May 21.


Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics.

Antoon JW, Liu J, Ponnapakkam AP, Gestaut MM, Foroozesh M, Beckman BS.

Cancer Chemother Pharmacol. 2010 May;65(6):1191-5. doi: 10.1007/s00280-009-1233-0. Epub 2010 Feb 14.


Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy.

Zimmermann MC, Tilghman SL, Boué SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, Fonseca JP, Corbitt C, Collins-Burow BM, Howell MH, Lacey M, Shih BY, Carter-Wientjes C, Cleveland TE, McLachlan JA, Wiese TE, Beckman BS, Burow ME.

J Pharmacol Exp Ther. 2010 Jan;332(1):35-45. doi: 10.1124/jpet.109.160382. Epub 2009 Oct 1.


Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells.

Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M.

J Med Chem. 2009 Sep 24;52(18):5748-52. doi: 10.1021/jm9009668.


Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence.

Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME.

Breast Cancer Res Treat. 2010 Jun;121(2):293-300. doi: 10.1007/s10549-009-0458-2. Epub 2009 Jul 12.


Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system.

Meacham WD, Antoon JW, Burow ME, Struckhoff AP, Beckman BS.

Exp Biol Med (Maywood). 2009 Nov;234(11):1253-63. doi: 10.3181/0902-MR-77. Epub 2009 Jun 22. Review.


A novel hypoxia-response element in the lactate dehydrogenase-B gene of the killifish Fundulus heteroclitus.

Rees BB, Figueroa YG, Wiese TE, Beckman BS, Schulte PM.

Comp Biochem Physiol A Mol Integr Physiol. 2009 Sep;154(1):70-7. doi: 10.1016/j.cbpa.2009.05.001. Epub 2009 May 8.


Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max).

Boué SM, Tilghman SL, Elliott S, Zimmerman MC, Williams KY, Payton-Stewart F, Miraflor AP, Howell MH, Shih BY, Carter-Wientjes CH, Segar C, Beckman BS, Wiese TE, Cleveland TE, McLachlan JA, Burow ME.

Endocrinology. 2009 May;150(5):2446-53. doi: 10.1210/en.2008-1235. Epub 2008 Dec 30.


Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.

Zhou C, Nitschke AM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan JA, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G.

Breast Cancer Res. 2008;10(6):R105. doi: 10.1186/bcr2210. Epub 2008 Dec 16.


Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.

Tang Y, Zhao DY, Elliott S, Zhao W, Curiel TJ, Beckman BS, Burow ME.

Int J Oncol. 2007 Oct;31(4):705-11.


Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis.

Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt PW, Beckman BS, McLachlan JA, Cleveland TE, Burow ME.

Clin Cancer Res. 2006 Dec 1;12(23):7159-64.


Integrin-linked kinase: a hypoxia-induced anti-apoptotic factor exploited by cancer cells.

Abboud ER, Coffelt SB, Figueroa YG, Zwezdaryk KJ, Nelson AB, Sullivan DE, Morris CB, Tang Y, Beckman BS, Scandurro AB.

Int J Oncol. 2007 Jan;30(1):113-22.


AKT regulation of estrogen receptor beta transcriptional activity in breast cancer.

Duong BN, Elliott S, Frigo DE, Melnik LI, Vanhoy L, Tomchuck S, Lebeau HP, David O, Beckman BS, Alam J, Bratton MR, McLachlan JA, Burow ME.

Cancer Res. 2006 Sep 1;66(17):8373-81.


Preserving and promoting our discipline: pharmacology students speak out.

Toews ML, Watts SW, Beckman BS.

Mol Interv. 2005 Feb;5(1):4-7. No abstract available.


PKC-mediated survival signaling in breast carcinoma cells: a role for MEK1-AP1 signaling.

Weldon CB, McKee A, Collins-Burow BM, Melnik LI, Scandurro AB, McLachlan JA, Burow ME, Beckman BS.

Int J Oncol. 2005 Mar;26(3):763-8.


Xenobiotic-induced TNF-alpha expression and apoptosis through the p38 MAPK signaling pathway.

Frigo DE, Vigh KA, Struckhoff AP, Elliott S, Beckman BS, Burow ME, McLachlan JA.

Toxicol Lett. 2005 Feb 15;155(2):227-38.


The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE.

J Cell Biol. 2004 Nov 8;167(3):469-78.


Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling.

Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, Dugan CM, Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM, Burow ME.

Int J Oncol. 2004 Jun;24(6):1473-80.


Novel ceramide analogs as potential chemotherapeutic agents in breast cancer.

Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS.

J Pharmacol Exp Ther. 2004 May;309(2):523-32. Epub 2004 Jan 23.


Mechanism of AP-1-mediated gene expression by select organochlorines through the p38 MAPK pathway.

Frigo DE, Tang Y, Beckman BS, Scandurro AB, Alam J, Burow ME, McLachlan JA.

Carcinogenesis. 2004 Feb;25(2):249-61. Epub 2003 Nov 6.


NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression.

Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, Beckman BS.

Exp Hematol. 2002 Dec;30(12):1419-27.


Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray.

Weldon CB, Scandurro AB, Rolfe KW, Clayton JL, Elliott S, Butler NN, Melnik LI, Alam J, McLachlan JA, Jaffe BM, Beckman BS, Burow ME.

Surgery. 2002 Aug;132(2):293-301.


Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.

Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS.

J Steroid Biochem Mol Biol. 2001 Nov;78(5):409-18.


NF-kappa B-mediated chemoresistance in breast cancer cells.

Weldon CB, Burow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS.

Surgery. 2001 Aug;130(2):143-50.


Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells.

Scandurro AB, Weldon CW, Figueroa YG, Alam J, Beckman BS.

Int J Oncol. 2001 Jul;19(1):129-35.


Cobalt induces heme oxygenase-1 expression by a hypoxia-inducible factor-independent mechanism in Chinese hamster ovary cells: regulation by Nrf2 and MafG transcription factors.

Gong P, Hu B, Stewart D, Ellerbe M, Figueroa YG, Blank V, Beckman BS, Alam J.

J Biol Chem. 2001 Jul 20;276(29):27018-25. Epub 2001 May 16.

Supplemental Content

Loading ...
Support Center